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Summary
Ovarian cancer treatment consists of surgical options and systemic antineoplastic therapy. Systemic medicamentous 
therapy, involves a choice of classic chemotherapy and targeted biological treatment. Cytotoxic drugs act nonspecifi cally on 
tumor cells, damaging also certain proportion of healthy cells in human body. Such drugs act on the basis of impact on the 
life cycle of cells. Some work throughout the whole cell cycle, phase nonspecifi cally, while others work somewhat more 
specifi cally for certain phase of cell cycle. Among cell cycle nonspecifi c antineoplastic drugs, a platinum compounds, cispla-
tin and carboplatin play the main role. A cell cycle phase specifi c activity is seen in a few groups of antineoplastic drugs, 
among which a signifi cant role in the therapy of ovarian cancer is played by taxanes paclitaxel and docetaxel, camptothecin 
analogue topotecan, podophyllotoxin etoposide, pyrimidine antagonist gemcitabine and anthracycline doxorubicin. In the 
treatment of ovarian cancer a signifi cant place is also held by two biological medicines, the so-called “on targeted drugs”, 
VEGF inhibitor bevacizumab and PARP inhibitor olaparib.
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SUSTAVNA TERAPIJA RAKA JAJNIKA 
– MEHANIZAM DJELOVANJA ANTINEOPLASTIČNH LIJEKOVA
Sažetak
U terapiji raka jajnika koriste se metode operativnog liječenja i sustavna antineoplastična terapija. Sustavna, medika-
mentozna terapija, podrazumijeva izbor klasičnih kemoterapeutika, kao i ciljanu, biološku terapiju. Citotoksični lijekovi 
djeluju nespecifi čno na same tumorske stanice, oštećujući tako i određenu proporciju zdravih stanica u organizmu. Takvi 
lijekovi djeluju na temelju utjecaja na životni ciklus stanice. Neki djeluju kroz cijeli stanični ciklus, nespecifi čno za fazu, dok 
određeni broj tih lijekova djeluje usko specifi čno za pojedinu fazu staničnog ciklusa. Od citotoksičnih lijekova nespecifi čnog 
djelovanja za fazu staničnog ciklusa u terapiji karcinoma jajnika temeljno mjesto zauzimaju spojevi platine, cisplatina i kar-
boplatina. Specifi čno djelovanje za pojedinu fazu staničnog ciklusa ima nekoliko skupina citotoksičnih lijekova, od kojih su 
najistaknutiji predstavnici u terapiji raka jajnika taksani paklitaksel i docetaksel, kamptotekinski analog topotekan, podofi -
lotoksin etopozid, pirimidinski antagonist gemcitabin te antraciklin doksorubicin. U liječenju raka jajnika značajno mjesto 
zauzimaju i dva biološka lijeka, tz v. ciljani lijekovi, VEGF inhibitor bevacizumab i PARP inhibitor olaparib. 
KLJUČNE RIJEČI: sustavna antineoplastična terapija, rak jajnika, kemoterapeutici, biološki lijekovi, stanični ciklus, cisplatina, 
karboplatina, taksani, paklitaksel, docetaksel, topotekan, etopozid, gemcitabin, doksorubicin, bevacizumab, olaparib.
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Ovarian cancer treatment consists of surgical 
options and systemic antineoplastic therapy. 
Systemic, medicamentous therapy, involves 
a choice of classic chemotherapy, cytotoxic drugs 
with eﬀ ect on cell cycle, and biological targeted 
treatment. 
Cytotoxic drugs, cytocids and cytostatics, act 
nonspecifi cally on tumorous cells, damaging also 
certain proportion of healthy cells in human body. 
Such drugs act on the basis of impact on the life 
cycle of cells. Some work throughout the whole 
cell cycle, phase-nonspecifi cally, while others 
work somewhat more specifi cally for certain 
phase of cell cycle. Cytotoxic drugs can act as al-
kylating agents throughout the whole cycle, as mi-
totic inhibitors, as antimetabolites and as topoi-
somerase enzyme complex inhibitors, in the pro-
cesses of DNA reparation.
These very mechanisms of their action are 
also the basis to group and classify these drugs 
(1-3).
Among cell cycle nonspecifi c antineoplastic 
drugs, in ovarian cancer therapy platinum com-
pounds, cisplatin and carboplatin play the main 
role. A cell cycle phase specifi c activity is seen in a 
few groups of antineoplastic drugs, among which 
a signifi cant role in the therapy of ovarian cancer 
is played by taxanes paclitaxel and docetaxel, 
camptotechin analogue topotecan, podophyllo-
toxin etoposide, pyrimidine antagonist gem-
citabine and anthracycline doxorubicin (1-6).
Platinum compounds, cisplatin and carbopl-
atin, act as alkylating agents. Alkylating drugs are 
cytotoxic, mutagenic and carcinogenic. They cause 
alkylation by forming intermediary susptances, 
translating alkyl group of biologically important 
molecules to the amino , carboxyl, sulfh ydryl or 
phosphate group. They alkylate nucleic acids, 
DNA and RNA, and also proteins. Most active 
spots of alkylation are guanine positions N-7 and 
O-6. Alkylation of guanine results in abnormal 
nucleotide sequences, mRNA encoding errors, ap-
pearance of DNA strand crossing, with the loss of 
replication ability, DNA chain breaks and other 
errors in transcription and translation of genetic 
material (7-9).
The most important toxicity factor is the ef-
fect on the interlocking of DNA chains, followed 
by damage to the parental DNA, and interruption 
of chains. Less signifi cant is the inactivation of the 
enzyme participants in DNA synthesis. Alkylat-
ing drugs act nonspecifi cally on the cell cycle 
phase, although dominant activity is seen in G2 
phase and at the transition from G1 to S phase of 
the cycle. In particular dose they destroy a specifi c 
percentage of cells. Resistance to these drugs is 
probably related to the ability of cells to recover 
damaged cellular nucleic acid, or to the inactiva-
tion by glutathione conjugation (9-11).
Cis-diaminodichlorplatinum (CDDP) or short 
cisplatin is a heavy metal, with an alkylating ac-
tion on DNA. It binds irreversibly, covalently to 
the DNA, usually at the location of the N7 atom of 
guanine or adenine and at the N3 atom of cytosine 
and uracil, thus forming the interlocking of chains 
and intra-chain N - 7 att raction, which cause con-
formational changes in DNA and aﬀ ect the DNA 
replication. It most commonly causes linking of 
two guanine bases in the same chain, a process ex-
tremely diﬃ  cult to repair (7). Other mechanisms of 
cisplatin cytotoxicity include mitochondrial dam-
age, reduced ATPase activity and revised me-
chanisms of cellular transport (10). Platinum tran-
sisomer anti-tumor activity is almost none. Resis-
tance to cisplatin involves changes in the 
transmembrane transport of the drug, variations 
in the intracellular concentration of glutathione 
(GSH) or sulfh ydryl containing proteins, and the 
above mentioned ability to repair DNA damage 
(12,13). Cisplatin is a drug that is well distributed 
in the body, without passing the blood-brain bar-
rier. The half-life of the drug in the plasma is three 
days, and may remain in tissues for months. Up to 
40% of the drug is excreted through the urinary 
tract in the fi rst 24 hours, about 15% of the drug is 
excreted unchanged in urine, and 10% of the drug 
is excreted in the bile. The toxicity of the drug is 
dose-dependent. Cisplatin is signifi cantly nephro-
toxic, neurotoxic for peripheral sensory nervous 
system and ototoxic. It is highly emetic, often 
causes myelosuppression and electrolyte imbal-
ance. In administering the drug it is necessary to 
monitor the work and excretory function of the 
kidneys, monitor the serum creatinine and elec-
trolytes, ensure good hydration and diuresis for 
the patient, and good antiemetic prophylaxis. 
Caution should be exercised when using cisplatin 
with other nephrotoxic drugs, and dose adjust-
ment is neccesary in case of changes in renal func-
tion, while complete discontinuation of treatment 
is neccesary in case of renal impairment. Cisplatin 
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interferes with renal elimination of bleomycin, et-
oposide and ifosfamide (7,10-12).
Carboplatin is a heavy metal with very simi-
lar action to cisplatin. It act as alkylating agent, 
predominantly causing the creation of interchain 
DNA crossing, non-specifi c to cell cycle phase (8). 
There is a signifi cant clinical cross-resistance be-
tween cisplatin and carboplatin. In contrast to the 
similarity in action, these drugs have a diﬀ erent 
profi le of toxicity (9). Carboplatin contains biden-
tate - dicarboxylic ligand, which slows the disso-
lution of carboplatin in harmful products. Carbo-
platin has a plasma half-life 2 to 3 hours, and 70% 
of the drug is excreted unchanged in the urine and 
via the metabolites. Carboplatin toxicity is also 
dose-dependent. Carboplatin is 45 times less toxic 
than cisplatin and therefore nephrotoxicity, oto-
toxicity and peripheral neuropathy are less fre-
quent. Myelosuppression, especially thrombocy-
topenia, is signifi cant, especially in patients previ-
ously treated with chemotherapy, and in patients 
with reduced creatinine clearance. Caution should 
be exercised when administering carboplatin in 
conjunction with other nephrotoxic or myelosup-
pressive agents (8,9). The required dose of carbo-
platin is calculated by creatinine clearance and 
Calvert’s formula, which determines the target 
dose by the AUC (Area under Curve)and in rela-
tion to glomerular fi ltration. It is important, dur-
ing the joint administration of taxanes and plati-
num compounds, to apply the taxane chemother-
apy prior to platinum.
Chemotherapeutic agents with specifi c ac-
tion on the cell cycle include the representatives of 
the three standard classes of cytotoxic drugs, plant 
alkaloids, antimetabolites and antitumor antibiot-
ics. The plant alkaloids include aforementioned 
taxanes, topotecan and etoposide. 
Taxanes are drugs which aﬀ ect the mitotic 
spindle in cell. They act as mitotic inhibitors or mi-
crotubule inhibitors, and since they “ freeze “ mi-
tosis at a given time, they are also known as mi-
totic poisons (14). They bind actively, reversibly 
and tightly to microtubule proteins, specifi cally to 
the beta tubulin, leading to their polymerization 
and then causing resistance to depolymerization 
(15,16). The result of action of the taxane is creation 
of nonfunctional microtubule polymer, which can 
not be decomposed by plan, and so the planned 
break down of the mitotic spindle cannot occur, 
nor can the planned process of mitosis proceed. 
Mitosis is stopped in the metaphase (17,18).
Paclitaxel is primarily isolated from the bark 
of Pacifi c yew trees. It is abundantly distributed in 
tissues and extensively metabolized by the micro-
somal cytochrome P450 system in the liver and 
excreted in bile and, in a large percentage, in the 
faeces, as hydroxylated products. Removing 
through the urinary tract is minimal. The concen-
tration in plasma is biphasic, and the elimination 
half-life lasts between 3 and 52 hours, on average 
23 hours. Depending on the dose, the toxicity of 
paclitaxel is achieved through myelosuppression, 
especially neutropenia, peripheral sensory neuro-
toxicity, basically reversible in character, myal-
gias, arthralgias and possible signifi cant hyper-
sensitivity reactions (19). Caution should be exer-
cised and dosage adjustment should be done in 
case of positive cardiac history, hepatic dysfunc-
tion, metabolic diseases such as diabetes and in 
patients who have previously been treated with 
neurotoxic drugs (19). Paclitaxel can interact with 
all drugs that are metabolized by the same hepatic 
cytochrome system. 
Docetaxel is a semisynthetic analog of 10 - 
DAB (deacetilbaccatine - III), an extract from Eu-
ropean yew needles. It also acts on the basis of in-
hibition of microtubule depolymerization, and the 
binding of docetaxel to microtubules does not al-
ter the number of protofi laments in microtubules. 
Docetaxel achieves high intracellular concentra-
tions and is retained in the cells for long. Like pa-
clitaxel, docetaxel is also extensively metabolized 
by cytochrome P450 system in the liver and ex-
creted predominantly in faeces, and small part in 
urine. The drug is slowly eliminated from the pe-
ripheral compartment. The pharmacokinetics of 
the drug is not aﬀ ected by the age and sex. 
Docetaxel is myelotoxic, can cause extreme fl uid 
retention, almost always causes alopecia, causes a 
transient peripheral sensory type neuropathy, and 
may cause non-specifi c reactions, such as general 
body weakness and changes in laboratory param-
eters. The drug should not be used in case of seri-
ous liver lesions. It also interacts with all drugs 
that are metabolized by the same metabolic path-
way, although the interactions observed were to 
considerably lesser extent than in paclitaxel. Giv-
en that a signifi cant myelosuppression is often 
 observed with docetaxel, especially neutropenia, 
Libri Oncol., Vol. 43 (2015), No 1–3, 59 – 65
62
myelopoesis growth factors are being applied by 
administering docetaxel (19,20).
Taxanes are carcinogenic, embryotoxic, feto-
toxic and mutagenic. They can cause expressed 
hypersensitivity reactions and it is therefore nec-
essary to apply desensitizing premedication (14).
Two other mentioned plant alkaloids, etopo-
side and topotecan, act by inhibiting topoisomer-
ase enzymatic system. DNA topoisomerases are 
enzymes that alter DNA topology, causing dis-
ruption of chains and refi lling them. They bind to 
DNA complex, causing cleavage of helix, allowing 
the unwinding of DNA in preparation for cell di-
vision. Topoisomerase I relaxes stranded DNA, 
creating a reversible single strand breaks in the 
double strand, so that the undisturbed parts of a 
single chain can slip past damaged parts, which 
will be corrected in a double superhelix. Topoi-
somerase II catalyzes the interruption and re-fi ll-
ing of double-stranded DNA and thereby enables 
relaxation of DNA superhelix bend, correcting 
nodes or improper entanglements. Topoisomer-
ases are essential in the processes of transcription, 
replication, mitosis. Group I and II enzymes are 
possible target site of action of cytotoxic drugs. 
That’s how the drugs interfere with transcription 
and replication, causing DNA damage, inhibiting 
the correction process and causing cell death. 
Topoisomerase inhibitors act phase – specifi c in 
the cell cycle, predominantly in the S phase and 
the late G2 phase of the cycle (21, 22).
A derivative of camptothecin, topotecan, in-
hibits topoisomerase I. The cytotoxic eﬀ ect is 
achieved through blocking of DNA reparation. It 
stabilizes the covalent complex of enzyme and 
single chain DNA, which is an intermediate prod-
uct of the catalytic mechanism. Consequently, a 
splitt ing of a single strand of DNA occurs. After 
the application, the drug is rapidly converted to 
the active lactone form in plasma. A minimal per-
centage is metabolized in the liver by microsomal 
cytochrome P450 system. Less then 10% of topote-
can is eliminated by metabolizing. The urine, feces 
and plasma yield one N - desmethyl metabolite, 
with a similar or lower activity than the parent 
compound. The drug is excreted in the urine. The 
main mode of clearance of topotecan is by hydro-
lysis of the lactone ring formation and forming of 
the open-ring carboxylate. Topotecan is predomi-
nantly myelotoxic and usually causes myelosup-
pression. It can cause non-specifi c reactions, such 
as body weakness, nausea, vomiting, digestive 
disturbances, arthralgia and myalgia. The drug 
should not be used in the damaged liver function, 
and in the case of low creatinine clearance it is 
necessary to reduce the dose (23,24).
Etoposide, epipodophyllotoxin, VP - 16, is a 
semisynthetic derivative of podophyllotoxin, a 
substance isolated from the mandrake plant. The 
drug acts as an nonintercalating inhibitor of the 
enzyme topoisomerase II, specifi cally in the late 
stages of the G2 and S phase of the cell cycle. By 
forming a complex of the DNA and topoisomer-
ase II enzyme it inhibits the synthesis of the DNA. 
The drug is at a high rate bound to plasma pro-
teins (mainly albumin) in the organism, and re-
duced levels of body protein may cause an in-
crease in the toxicity of the drug. It is metabolized 
by the liver glucuronidation to less active metabo-
lites. Forty per cent of the supstance is excreted in 
the urine as unchanged and degraded drug, and 
the remaining percentage of excretion of the drug 
has not been fully explored. The dominant toxic 
eﬀ ect is myelosuppression. It is emetic, can cause 
alopecia, hypotension during rapid administra-
tion and disturbance of liver function tests. Cau-
tion should be exercised in case of renal dysfunc-
tion, and dose reduction in the case of liver dys-
function. The toxicity of the drug is increased by 
calcium channel inhibitors and methotrexate 
(25,26).
Among the cell cycle phase specifi c cytotoxic 
drugs in the treatment of ovarian cancer there are 
also A pyrimidine base antagonist gemcitabine 
and anti-tumor antibiotic doxorubicin also belong 
among the cell cycle phase specifi c cytotoxic drugs 
in the treatment of ovarian cancer. 
Gemcitabine is an antimetabolite, an analog 
of deoxycytidine. In the current form it is a pro-
drug, which is phosphorylated by deoxycytidine 
kinase to the active form, gemcitabine diphos-
phate (dFdCDP) and gemcitabine triphosphate 
(dFdCTP) immediately after the entrance to the 
cell. Both active substrates then inhibit processes 
required for DNA synthesis. The most likely 
mechanism of cytotoxicity of gemcitabine is incor-
poration of dFdCDP and dFdCTP in DNA. After 
incorporation of gemcitabine nucleotides in ex-
tending DNA chain, one other deoxynucleotide is 
added at the end and then the polymerases can no 
longer continue acting in the extension of the 
DNA chain. This masked chain termination actu-
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ally locks remedy in the chain of DNA, since the 
enzymes then can’t remove it. Gemcitabine me-
tabolites simultaneously act on other cell regula-
tory processes, all in a general manner of blocking 
and inhibiting cell growth. This is the so-called 
self-potentiation of gemcitabine, which a lot of 
other cytotoxic drugs do not posess. As regardsthe 
phase of the cell cycle, gemcitabine fi rst destroys 
the cells in S phase, and then blocks progression 
through the G1 phase to the S phase. The drug is 
metabolized intracellularly in the liver, plasma 
and peripheral tissues. It is almost completely ex-
creted in urine, as the active drug and metabolite. 
Toxicity depends on the applied dose of the drug. 
It expresses myelotoxicity, is emetic, causes indi-
gestion, rash and hypersensitivity reactions are 
possible. Caution should be exercised in patients 
with impaired hepatic and renal function, and in 
patients with ongoing radiotherapy (27-29).
The antitumor antibiotic doxorubicin, or hy-
droxydaunorubicin, is anthracycline, which pre-
vents DNA synthesis in S phase of the cell cycle. 
The substance is a secondary metabolite of aerobic 
bacteria of the genus Streptomyces. In the treat-
ment of ovarian cancer a liposomal doxorubicin is 
used, where the doxorubicin is encapsulated in 
long-circulating liposome (microscopic vesicle 
with bilayer phospholipid membrane). Liposomal 
doxorubicin has a slower plasma clearance than 
the standard doxorubicin. The mechanism of drug 
and metabolism is unchanged compared to doxo-
rubicin. Drug acts as intercalating inhibitor of 
topoisomerase II, intercalating between base pairs 
of DNA, but also generates free radicals, which 
cause damage to cell membranes, DNA and pro-
teins, inhibits preribosomal DNA and RNA. More 
than two-thirds of the drug is bound to plasma 
proteins. It is rapidly metabolized in the liver to 
other compounds with cytotoxic activity. The 
drug is slower released, than the hepatic mecha-
nisms can metabolize, so in this way the hepatic 
system is unsaturated and that causes extension of 
the increased levels of drug and metabolites in the 
plasma. Liposomal doxorubicin is hematotoxic. 
Beside the hematosupression, can also cause non-
specifi c problems in terms of fatigue, digestive 
disorders, emesis, infusion reactions, which dis-
appear upon termination of the application of the 
drug, can cause a “recall” reactions, palmo-plan-
tar erythrodisestesia and other allergic reactions. 
Dose modifi cation is necessary in the event of an 
increase in serum bilirubin, and a drug must not 
be used in case of congestive heart failure. Dexra-
zoxane inhibits the cardiotoxicity of doxorubicin, 
and mitomycin and trastuzumab increase it. Mer-
captopurine increases the risk of doxorubicin hep-
atotoxicity (30- 32).
In the treatment of ovarian cancer a signifi -
cant place is held by two biological medicines, the 
so-called “on targeted drugs”, bevacizumab and 
olaparib.
Bevacizumab is an inhibitor of vascular en-
dothelial growth factor (VEGF). It is a recombi-
nant humanized monoclonal antibody, produced 
by recombinant DNA technology from a Chinese 
hamster ovary cell. The drug binds selectively to 
VEGF (a key factor in vasculogenesis and angio-
genesis of tumor) and thus prevents binding of 
VEGF to its receptors, VEGFR-1 and VEGFR-2, on 
the surface of endothelial cells. Neutralizing the 
biological activity of VEGF bevacizumab causes a 
reduction of tumor vascularization and normal-
ization of the remaining tumor vasculature, inhib-
its the formation of new vasculature of tumor, 
thereby inhibiting growth of the tumor itself. The 
pharmacokinetics of the drug in doses of conven-
tional administration is linear. The metabolism of 
the drug has not yet been fully established, it is 
similar to that of endogenous IgG molecules, fi rst 
through proteolytic catabolism throughout the 
body, including endothelial cells, rather than 
elimination through the kidneys and liver (34-36). 
Men have a higher clearance of the drug, com-
pared to women. The half-life is about 19 days. 
The rapid clearance of the drug was observed in 
patients with lower values of serum albumin and 
in the case of pronounced tumor disease burden. 
Bevacizumab should not be administered within 
28 days of any surgery or invasive diagnostic pro-
cedure. It can cause thromboembolic incidents, 
gastrointestinal perforation, wound dehiscence, 
hypertension, bleeding, nephrotic syndrome and 
various complications of wound healing. As with 
the use of all monoclonal antibodies, the cytokine 
releasing syndrome associated with infusion (IR-
CRS) is also possible with bevacizumab, especially 
during the fi rst administration of the drug, in the 
form of tremors, fever, hypotension, bronchospasm 
and angioedema, which gradually decrease with 
the duration of drug administration and also 
the duration of treatment in general, and the 
symptoms can be reduced by technical measures, 
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changing the way and speed of administration, as 
well as the application of symptomatic therapy 
(34-36).
Olaparib is poly (ADP - ribose) polymerase 
(either synthase or transferase, PARP) inhibitor. 
PARP inhibitors are necessary in the repair of 
DNA single-strand breaks, when after modifi ca-
tions of chromatin, PARP dissociates from DNA 
by automodifi cation, to allow easier access to and 
repair of strand by cutt ing bases. When olaparib 
bounds to the location of activity of PARP in the 
DNA, it prevents dissociation of PARP and an-
chors them in the chain of DNA, thus preventing 
the repair process. In the dividing cell this produc-
es a double fracture of chains, where the replica-
tion fork comes to PARP-DNA junction. In normal 
cells, homologous recombinative repairs, for 
which functional BRCA 1 and 2 genes are necce-
sary, manage to fi x these double strand breaks 
(36,37). In the absence of functional BRCA 1 and 2 
these reparation processes are not successful. 
Therefore, the stronger activity of olaparib is re-
corded in the mutated BRCA 1 and BRCA 2 cells, 
compared to wild type cells, and a 1000 times 
higher sensitivity of mutant cells to the drug. In 
these cells unsuccessful repairs are being replaced 
by the wrong ways and att empts of reparations, 
resulting in a distinct genomic instability, which 
after a series of such processes becomes intolera-
ble and such cells die (38). Olaparib is adminis-
tered orally and achieves peak plasma concentra-
tions in two hours after administration. The drug 
showed no tendency to accumulate in the organ-
ism, half-life is about 12 hours and is metabolized 
via CYP3A4 / 5 system in the liver. The drug is 
excreted in both urine and faeces, mostly as me-
tabolites. Caution should be exercised in case of 
renal or hepatic dysfunction. It causes frequent 
side eﬀ ects on the digestive system, as well as he-
matological toxicity. Side eﬀ ects are usually mild 
or moderate in character, especially the side ef-
fects on the digestive system and therefore do not 
require discontinuation of treatment. It can inter-
act with all drugs that induce or inhibit CYP3A4 / 
5 system. The drug is genotoxic, mutagenic, em-
bryotoxic and fetotoxic and can cause reproduc-
tive toxicity (39).
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